One Fraction Size Does Not Fit All: Patient Preferences for Hypofractionated Radiation Therapy From a Discrete Choice Experiment.

[1]  D. Street,et al.  Respondent Understanding in Discrete Choice Experiments: A Scoping Review , 2020, The Patient - Patient-Centered Outcomes Research.

[2]  S. Beriwal,et al.  Breast, Prostate, and Rectal Cancer: Should 5-5-5 Be a New Standard of Care? , 2020, International Journal of Radiation Oncology*Biology*Physics.

[3]  I. El Naqa,et al.  Radiation Fractionation Schedules Published During the COVID-19 Pandemic: A Systematic Review of the Quality of Evidence and Recommendations for Future Development , 2020, International Journal of Radiation Oncology*Biology*Physics.

[4]  C. Parker,et al.  Prostate Cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  K. Hoffman,et al.  Hypofractionated Radiation Therapy for Localized Prostate Cancer: Executive Summary of an ASTRO, ASCO and AUA Evidence-Based Guideline , 2019, The Journal of urology.

[6]  Alan R. Ellis,et al.  Discrete Choice Experiments in Health Economics: Past, Present and Future , 2018, PharmacoEconomics.

[7]  I. Kaplan,et al.  Patient Reported Outcomes in NRG Oncology RTOG 0938, Evaluating Two Ultrahypofractionated Regimens for Prostate Cancer. , 2018, International journal of radiation oncology, biology, physics.

[8]  J. Mahlich,et al.  Patient Preferences and Urologist Judgments on Prostate Cancer Therapy in Japan , 2018, American journal of men's health.

[9]  Peter Vickerman,et al.  How well do discrete choice experiments predict health choices? A systematic review and meta-analysis of external validity , 2018, The European Journal of Health Economics.

[10]  S. Thompson,et al.  The enablers, barriers and preferences of accessing radiation therapy facilities in the rural developed world – a systematic review , 2017, BMC Cancer.

[11]  M. Hudson,et al.  Do patients and health care providers have discordant preferences about which aspects of treatments matter most? Evidence from a systematic review of discrete choice experiments , 2017, BMJ Open.

[12]  L. Eliasson,et al.  Patients' Preferences for the Treatment of Metastatic Castrate-resistant Prostate Cancer: A Discrete Choice Experiment. , 2017, Clinical therapeutics.

[13]  Alison C. Tree,et al.  The Role of Hypofractionated Radiotherapy in Prostate Cancer , 2017, Current Oncology Reports.

[14]  Maarten J. IJzerman,et al.  Statistical Methods for the Analysis of Discrete Choice Experiments: A Report of the ISPOR Conjoint Analysis Good Research Practices Task Force. , 2016, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[15]  Bas Donkers,et al.  Sample Size Requirements for Discrete-Choice Experiments in Healthcare: a Practical Guide , 2015, The Patient - Patient-Centered Outcomes Research.

[16]  L. Longworth,et al.  Does convenience matter in health care delivery? A systematic review of convenience-based aspects of process utility. , 2014, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[17]  Caroline Vass,et al.  Risk as an Attribute in Discrete Choice Experiments: A Systematic Review of the Literature , 2014, The Patient - Patient-Centered Outcomes Research.

[18]  E. Steyerberg,et al.  Patients' and urologists' preferences for prostate cancer treatment: a discrete choice experiment , 2013, British Journal of Cancer.

[19]  Sarah Ronaldson,et al.  Ordinal preference elicitation methods in health economics and health services research: using discrete choice experiments and ranking methods. , 2012, British medical bulletin.

[20]  Joanna Coast,et al.  Using qualitative methods for attribute development for discrete choice experiments: issues and recommendations. , 2012, Health economics.

[21]  Mandy Ryan,et al.  Discrete choice experiments in health economics: a review of the literature. , 2012, Health economics.

[22]  M. Stockler,et al.  Survival gains needed to offset persistent adverse treatment effects in localised prostate cancer , 2012, British Journal of Cancer.

[23]  Masatoshi Kudo,et al.  Identifying and prioritizing strategies for comprehensive liver cancer control in Asia , 2011, BMC health services research.

[24]  Andrew Lloyd,et al.  Conjoint analysis applications in health--a checklist: a report of the ISPOR Good Research Practices for Conjoint Analysis Task Force. , 2011, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[25]  G. Elwyn,et al.  Implementation Science BioMed Central Debate , 2009 .

[26]  John M. Rose,et al.  Asymmetric preference formation in willingness to pay estimates in discrete choice models , 2008 .

[27]  Ola Svenson,et al.  Patient‐focussed decision‐making in early‐stage prostate cancer: insights from a cognitively based decision aid , 2004, Health expectations : an international journal of public participation in health care and health policy.

[28]  J. Concato,et al.  Treatment Decisions for Localized Prostate Cancer Asking Men What ’ s Important , 2000 .

[29]  Deborah Marshall,et al.  Constructing experimental designs for discrete-choice experiments: report of the ISPOR Conjoint Analysis Experimental Design Good Research Practices Task Force. , 2013, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.